A director proposes selling 1,203 shares of Quest Diagnostics (NYSE: DGX).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Quest Diagnostics director Gary M. Pfeiffer has proposed selling 1,203 common shares, valued at $292,329, on approximately October 26, 2026. These shares originated from restricted stock vesting on May 15, 2026, received as compensation. The transaction will be handled by Fidelity Brokerage Services LLC on the NYSE.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.